Lifeboat Foundation

TEL AVIV — Critically ill COVID-19 patients recovered rapidly from respiratory failure after three days of treatment with RLF-100, a therapy granted fast-track designation in the United States, two drug companies said Sunday.

Geneva-based Relief Therapeutics Holdings AG RFLB.S has a patent for RLF-100, or aviptadil, a synthetic form of a natural peptide that protects the lung. US-Israeli NeuroRx Inc. partnered with Relief to develop the drug in the United States.

In June the US Food and Drug Administration granted fast-track designation to RLF-100 for treatment of respiratory distress in COVID-19.

Scientists have traced mysterious radio signals detected on Earth to a dead star within our Milky Way galaxy.

The millisecond-long burst of radiation was emitted by a magnestar — a type of star with an extremely powerful magnetic field — roughly 14,000 light-years away, according to a study.

Known as fast radio bursts (FRBs), signals such as these have baffled scientists for years and typically originate from far beyond the Milky Way.

Building a sustainable future.

Record Holder.

Continue reading “Dubai has taken 3D printing to a whole new level” »

A new machine learning program called MISIM can figure out what a snippet of code is meant to do and offer up new code to make it faster or more efficient.

“Oxygen tanks are not allowed in the battlefield because they risk exploding and are therefore considered too dangerous,” he said. “However, we have seen that in wars that Israel has fought, the complications related to the evacuation of injured soldiers without the possibility of providing them with oxygen in the meantime has caused several fatalities.”

The group started to work on a solution that would not only eliminate the dangers related to traditional oxygen tanks, but would also make it easier for the oxygen to be carried around.

The result is a device about 45×18 centimeters in size that produces oxygen without the need of a thermo-dynamic process.

We investigate a suspected very massive star in one of the most metal-poor dwarf galaxies, PHL 293B. Excitingly, we find the sudden disappearance of the stellar signatures from our 2019 spectra, in particular the broad H lines with P Cygni profiles that have been associated with a massive luminous blue variable (LBV) star. Such features are absent from our spectra obtained in 2019 with the Echelle Spectrograph for Rocky Exoplanet- and Stable Spectroscopic Observation and X-shooter instruments of the European Southern Observatory’s Very Large Telescope. We compute radiative transfer models using cmfgen, which fit the observed spectrum of the LBV and are consistent with ground-based and archival Hubble Space Telescope photometry. Our models show that during 2001–2011, the LBV had a luminosity L_* = 2.5–3.5 × 10⁶ L_⊙, a mass-loss rate ˙ M = 0.005 − 0.020 M ⊙ yr⁻¹, a wind velocity of 1000 km s⁻¹, and effective and stellar temperatures of T_eff = 6000–6800 and T_* = 9500–15 000 K. These stellar properties indicate an eruptive state. We consider two main hypotheses for the absence of the broad emission components from the spectra obtained since 2011. One possibility is that we are seeing the end of an LBV eruption of a surviving star, with a mild drop in luminosity, a shift to hotter effective temperatures, and some dust obscuration. Alternatively, the LBV could have collapsed to a massive black hole without the production of a bright supernova.

READ: Avalon GloboCare forges partnership with Austrian university to develop coronavirus vaccine

It noted that treatment with AVA-001 was generally well tolerated with minimal toxicities and adverse side effects. No neurotoxicity or greater than Grade-1 cytokine release syndrome was observed in this cohort of patients treated with AVA-001. All patients who achieved CR successfully proceeded to allogeneic bone marrow transplant with curative intent.

Purdue University innovators are working on inventions to use micro-chip technology in implantable devices and other wearable products such as smart watches to improve biomedical devices, including those used to monitor people with glaucoma and heart disease.

The Purdue team developed a fully implantable radio-frequency transmitter chip for wireless sensor nodes and biomedical devices. The research is published in the journal IEEE Transactions on Circuits and Systems II. The transmitter chip consumes lowest amount of energy per digital bit published to date.

The transmitter works in a similar fashion to communication technology in mobile phones and smart watches, but the Purdue transmitter has an unprecedented level of miniaturization and low-energy consumption that it can be implanted into an eye to monitor pressure for a glaucoma patient or into another part of the body to measure data related to heart functions.

Singapore researchers have developed “electronic skin” capable of recreating a sense of touch, an innovation they hope will allow people with prosthetic limbs to detect objects, as well as feel texture, or even temperature and pain.

The device, dubbed ACES, or Asynchronous Coded Electronic Skin, is made up of 100 small sensors and is about 1 square centimeter (0.16 square inch) in size.

The researchers at the National University of Singapore say it can process information faster than the human nervous system, is able to recognise 20 to 30 different textures and can read Braille letters with more than 90% accuracy.